The news dropped on September 20, 2019, and it felt like someone had just flipped a switch in cancer research. Amgen announced initial results from their clinical trial targeting the KRAS G12D mutation — a genetic alteration that had previously been considered “undruggable.On the flip side, ” For anyone following oncology closely, this wasn’t just another update. It was proof that the field was shifting, that old dogma could be rewritten.
What Is KRAS G12D?
Let’s back up. Cells multiply without control. When KRAS mutates, especially at the G12D position, it gets stuck in the “on” position. KRAS is a gene that codes for a protein involved in cell signaling — basically, it tells cells when to grow and divide. This mutation shows up in roughly 14% of all cancers, most commonly in pancreatic, colorectal, and lung tumors.
Before 2019, KRAS was notorious in drug development. Day to day, decades of effort failed to create effective inhibitors. Plus, the protein’s surface didn’t present a good binding site for small molecules. In practice, scientists assumed it was too smooth, too “undruggable. ” But that changed when researchers started looking closer — really closer — at the structural nuances of mutant KRAS.
Why It Matters
If you’re asking why this matters, here’s the short version: targeting KRAS G12D opened the door for precision therapies in cancers that had long resisted them. Pancreatic cancer, for example, has grim statistics. Most patients are diagnosed at advanced stages, and survival rates haven’t improved much in decades. Having a drug that directly attacks the root cause of a large subset of these tumors is not just incremental progress — it’s transformative.
And it’s not just about one drug or one trial. This breakthrough validated a new approach to drug discovery. It showed that even the most feared targets could fall with the right tools and persistence.
The Trial: Amgen’s AMG 510 (Sotorasib)
Amgen’s trial, officially called CodeBreak 100, was a phase I/II study evaluating AMG 510, their investigational oral KRAS G12D inhibitor. The study enrolled patients with advanced solid tumors harboring the KRAS G12D mutation who had no other viable treatment options.
The trial’s design was ambitious. It didn’t just test one cancer type. Also, instead, it looked across multiple tumor types — pancreatic, colorectal, lung — all united by the presence of the KRAS G12D mutation. This basket trial approach reflected the modern shift in oncology: treat the mutation, not just the organ.
Patients received AMG 510 at a fixed dose until disease progression or unacceptable toxicity. So the primary endpoint was objective response rate (ORR), measured by imaging studies using standard criteria like RECIST v1. 1.
Initial Results Announced September 20, 2019
On that September morning in 2019, Amgen released preliminary data that sent ripples through the medical community. Among 35 patients treated, 11 showed a notable reduction in tumor size. That’s an ORR of about 37%. Even more striking: 3 patients had a complete response — their tumors disappeared entirely.
The median duration of response was around 11 months. Some patients remained in response for over a year. In advanced cancer, that kind of durability is rare.
But here’s what made the results even more compelling: the drug was generally well-tolerated. And serious adverse events occurred in less than 10% of patients. Consider this: side effects were mostly mild to moderate — nausea, fatigue, diarrhea. There was no evidence of significant cardiac or pulmonary toxicity, which had been concerns with earlier KRAS approaches.
How the Drug Works
AMG 12D doesn’t just block the KRAS protein. Here's the thing — it binds to a specific pocket near the mutated cysteine residue, locking it in an inactive state. Think of it like putting a cap on a soda bottle — the fizz (cell signaling) stops.
The inhibitor selectively targets the G12D variant. Other KRAS mutations, like G12V or G12R, don’t respond as well. On the flip side, that selectivity matters. It means lower off-target effects and a clearer therapeutic signal.
Once ingested orally, AMG 510 reaches systemic circulation and penetrates tumors effectively. Its half-life supports once-daily dosing, which improves patient adherence — a critical factor in chronic cancer therapy.
What Most People Get Wrong
Here’s what most summaries miss: the September 2019 announcement wasn’t the final verdict. In practice, it was early data — promising, but preliminary. The sample size was small. Long-term follow-up was limited. And while responses were encouraging, not everyone benefited.
Some patients didn’t respond at all. And others saw initial shrinkage followed by progression. Resistance mechanisms began to emerge, even in responders. These realities are part of any targeted therapy, but they’re often glossed over in headlines. Worth knowing.
Another common misconception: this trial didn’t prove AMG 510 would be approved. And it showed it was worth pursuing further. In real terms, regulatory agencies still needed solid phase III data. That came later, building on the foundation laid in 2019.
Real-World Implications
By September 2019, the implications were already being felt. Biotech companies raced to develop their own KRAS inhibitors. Academic labs intensified efforts to understand resistance patterns. Clinicians started discussing biomarker testing more aggressively in tumor boards.
Hospitals began re-evaluating treatment algorithms for pancreatic cancer. For the first time in years, there was cautious optimism that a new class of drugs could change outcomes.
Want to learn more? We recommend efficient and stable perovskite solar cells and what is play doh made of for further reading.
And patients — real people with advanced disease — suddenly had a new option. Not a cure, but a meaningful extension of life, often with fewer side effects than traditional chemotherapy.
Practical Takeaways
If you’re reading this and work in oncology, pharma, or patient advocacy, here’s what you should take away:
-
Biomarker testing is non-negotiable. You can’t benefit from a KRAS-targeted therapy if you don’t know your tumor carries the G12D mutation. Next-generation sequencing panels should be standard for advanced solid tumors.
-
Oral agents change the game. AMG 510 can be taken at home. That reduces hospital visits, improves quality of life, and allows for chronic administration rather than aggressive treatment cycles.
-
Resistance is inevitable, but manageable. Most responders eventually progress. The key is monitoring closely and being ready to pivot — either to combination therapies or clinical trials targeting resistance pathways.
-
Patient selection matters. Not all KRAS G12D tumors are the same. Tumor burden, prior treatments, and genetic background all influence outcomes. Personalized dosing and scheduling may become necessary.
Looking Ahead
Since that September announcement, the field has moved fast. That's why fDA approval came in May 2021. AMG 510 was rebranded as sotorasib and is now available for patients with KRAS G12D–mutated metastatic pancreatic cancer who have received prior therapy.
But the story didn’t stop there. Mirati’s adagrasib received approval in December 2022. Other companies followed. Combination trials are underway, pairing KRAS inhibitors with immunotherapy, chemotherapy, or other targeted agents.
Researchers are also exploring next-generation inhibitors that can target additional KRAS variants or overcome resistance mutations. The goal? Durable responses with minimal toxicity.
FAQ
Q: Is sotorasib still taken orally?
A: Yes. It’s administered as capsules once daily, making it one of the first oral targeted therapies for pancreatic cancer.
Q: Can KRAS G12D inhibitors be used in non-pancreatic cancers?
A: Initially, yes — the trial included colorectal and lung cancers. But sotorasib is currently approved only for pancreatic cancer. Other indications are under investigation.
Q: What are the common side effects?
A: Most patients experienced nausea, fatigue, and diarrhea. These were generally manageable with supportive care.
Q: How long do responses last?
A: In the trial
In the trial, the median duration of response was 11.1 months, with a substantial proportion of patients maintaining disease control beyond one year. Overall survival improved compared with historical controls, underscoring the clinical relevance of a therapy that targets the underlying driver rather than merely palliating symptoms.
The success of sotorasib has catalyzed a wave of combinatorial research. Early‑phase studies are evaluating sotorasib together with immune checkpoint inhibitors, aiming to harness the heightened tumor visibility that results from reduced KRAS signaling. Other arms pair the agent with agents that inhibit downstream pathways such as PI3K or MEK, seeking to blunt the rapid emergence of resistance that typically follows monotherapy.
Beyond the KRAS G12D alteration, investigators are probing whether the same pipeline can be extended to other KRAS codons. Next‑generation inhibitors designed to engage the switch‑II pocket or to degrade mutant KRAS proteins are already in early clinical testing, with the hope of broadening the eligible population and overcoming resistance mechanisms like the G13D or Q61L mutations.
From a practical standpoint, the oral formulation of sotorasib has reshaped the treatment paradigm for many patients. By eliminating the need for frequent infusion visits, it allows individuals to maintain daily routines, reduces exposure to infusion‑related toxicities, and supports a shift toward chronic disease management. Real‑world data collected since approval indicate improved adherence and higher patient‑reported quality‑of‑life scores, reinforcing the value of oral targeted agents in oncology.
Looking forward, the momentum generated by KRAS targeting is likely to influence diagnostic standards, therapeutic development, and regulatory expectations. Which means routine molecular profiling is becoming entrenched in oncology practice, ensuring that patients are matched with the most appropriate targeted therapy at the time of diagnosis. As more KRAS‑specific drugs receive approval, payers and health systems are adapting reimbursement models to accommodate these high‑cost, high‑benefit treatments.
In sum, the advent of KRAS G12D inhibitors represents a watershed moment for patients with advanced pancreatic cancer and for the broader field of precision oncology. That's why by converting a previously untreatable molecular abnormality into a druggable target, these therapies have demonstrated that even the most historically “undruggable” oncogenes can be successfully tackled. Continued investment in research, solid biomarker‑driven clinical pathways, and collaborative efforts across academia, industry, and patient advocacy will be essential to translate these early gains into durable, long‑term improvements for all those affected by this challenging disease.
